Abstract:
This invention is directed to compounds of formula (I): where r, q, R, R2, R3, R4, R5a, R5b, R5c, R6a, R6b, R6c, R7, R8, and R9 are described herein, as single stereoisomers or as mixtures of stereoisomers, or pharmaceutically acceptable salts, solvates, clathrates, polymorphs, ammonium ions, N-oxides or prodrugs thereof; which are leukotriene A4 hydrolase inhibitors and therefore useful in treating inflammatory disorders. Pharmaceutical compositions comprising the compounds of the invention and methods of preparing the compounds of the invention are also disclosed.
Abstract:
This invention provides novel dihydropyridine derivatives of the formula I having protein tyrosine kinase inhibitory activity, to process for the manufacture thereof and to the use thereof for the treatment of c-Met-mediated diseases or c-Met-mediated conditions.
Abstract:
This invention is directed to compounds of formula (I): where r, q, R, R2, R3, R4a, R4b, R4c, R5a, R5b, R5c, R6a, R6b, R6c, R7, R8, R9 and R10 are described herein, or pharmaceutically acceptable salts, solvates, polymorphs, ammonium ions, N-oxides or prodrugs thereof; which are leukotriene A4 hydrolase inhibitors and which are therefore useful in treating inflammatory disorders. Pharmaceutical compositions comprising the compounds of the invention and methods of using and preparing the compounds of the invention are also disclosed.
Abstract:
N-Heterocyclic derivatives of the formula (I): are described herein, as well as other N-heterocycles, as inhibitors of nitric oxide synthase. Pharmaceutical compositions containing these compounds, methods of using these compounds as inhibitors of nitric oxide synthase and processes for synthesizing these compounds are also described herein.
Abstract:
N-Heterocyclic derivatives of the formula (I): are described herein, as well as other N-heterocycles, as inhibitors of nitric oxide synthase. Pharmaceutical compositions containing these compounds, methods of using these compounds as inhibitors of nitric oxide synthase and processes for synthesizing these compounds are also described herein.
Abstract:
This invention is directed to compounds of formula (III): ##STR1## wherein B, C, D, E, R.sup.1, R.sup.2 and R.sup.3 are disclosed herein. These compounds are disclosed as being useful as anti-coagulants.
Abstract:
Provided is a music note indicating method for an electronic piano, a mobile terminal, an electronic piano and a music note indicating system. The electronic piano includes a keyboard with a plurality of keys, a controlling device and a plurality of LED indicating lamps. The plurality of LED indicating lamps are located in a plane parallel to the keyboard. The method includes: obtaining a music score information of a predetermined music score by a mobile terminal; analyzing the music score information to generate a music note sequence comprising at least one first music note data by the mobile terminal; generating a control signal according to the at least one first music note data and sending the control signal to the controlling device by the mobile terminal; and controlling the plurality of LED indicating lamps to indicate the music note sequence according to the control signal by the controlling device.
Abstract:
The present invention is directed to diagnostic methods based upon the detection of peptides derived from the degradation of CA125. In particular, it is concerned with assays of urine samples collected from women for the purpose of determining whether they are at increased risk for having ovarian cancer, have decreased their risk as the result of clinical or non-clinical procedures, to monitor the efficacy of a treatment method, or to determine whether cancer has recurred or advanced.
Abstract:
A radiographic system(100) is provided wherein a single X-ray detector can be handled freely using a cable and which can prevent an operator or a patient from being troubled by the cable. The radiographic system(100) comprises a radiographic panel(5) configured to radiograph in two dimensions a radiation exposed to a subject and output radiation image data, a cable(6) for the supply of electric power to the radiographic panel and transfer of the radiation image data, a conveyance unit(8) for conveying the cable in a predetermined direction, a cable length adjusting unit(7) provided in the conveyance unit to adjust the length of the cable, and a movement control unit(72) configured to move the conveyance unit in accordance with a tilting direction of the cable from the cable length adjusting unit to the radiographic panel.
Abstract:
The present invention relates to CCR5 receptor antagonists of formulae (1a) or (1b): enantiomers, diastereomers, salts and solvates thereof wherein R1, R2, R3, R4, R5, and R7 are as defined herein. The invention further includes a method of CCR5-mediated disorders employing such compounds.